200028.SHE China National Accord Medicines Corp Ltd
- Market cap
- HKD 7.54B
- P/E
- 6.3x
- P/B
- 0.34x
- ROE
- 6.4%
- Dividend yield
- 5.73%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 200028.SHE undervalued?
Graham numberThe Graham number of China National Accord Medicines Corp Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China National Accord Medicines Corp Ltd fundamental analysis
No fundamental analysis for China National Accord Medicines Corp Ltd yet.
China National Accord Medicines Corp Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China National Accord Medicines Corp Ltd
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. The company offers new and special drugs and medications for chronic diseases. It also provides traditional Chinese medicine, Western medicine, rehabilitation therapy, and various medical-related resources, as well as chemical drugs, OTC drugs, and health products. The company was formerly known as Shenzhen Health Mineral Water Corp…
Full company profileChina National Accord Medicines Corp Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China National Accord Medicines Corp Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 41.2B | 41.3B | 43.1B | 52.8B | 59.6B | 68.4B | 73.4B | 75.5B | 74.4B | 71.5B | 72.5B |
| Gross Profit | 4.59B | 4.44B | 5.08B | 5.87B | 7.03B | 7.99B | 8.88B | 9.01B | 8.20B | 7.84B | 7.28B |
| Operating Income | 1.56B | 1.46B | 1.67B | 1.83B | 2.16B | 1.95B | 2.31B | 2.47B | 573M | 1.47B | 1.72B |
| EBITDA | 1.89B | 1.70B | 1.98B | 2.25B | 2.58B | 2.47B | 2.82B | 4.15B | 1.06B | 1.47B | 1.80B |
| Net Income | 1.19B | 1.06B | 1.21B | 1.27B | 1.40B | 1.34B | 1.49B | 1.60B | 642M | 1.11B | 1.21B |
| EPS | 2.15 | 1.90 | 2.18 | 2.28 | 2.52 | 2.40 | 2.67 | 2.87 | 1.15 | 1.99 | 1.98 |
| Balance Sheet | |||||||||||
| Total Assets | 21.3B | 22.3B | 28.9B | 33.5B | 39.6B | 42.8B | 42.6B | 47.6B | 47.6B | 49.1B | 48.2B |
| Total Liabilities | 12.4B | 12.4B | 15.0B | 18.2B | 22.7B | 24.8B | 23.2B | 26.6B | 26.8B | 27.5B | 26.3B |
| Shareholders' Equity | 8.45B | 9.40B | 11.6B | 12.8B | 13.9B | 14.9B | 16.1B | 17.4B | 17.7B | 18.6B | 18.9B |
| Cash & Short-term Investments | 3.52B | 4.19B | 8.09B | 8.88B | 6.00B | 5.13B | 6.02B | 6.50B | 7.41B | 7.80B | 5.93B |
| Total Debt | 1.55B | 1.60B | 2.64B | 3.24B | 3.70B | 4.23B | 3.52B | 4.06B | 4.39B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.47B | 1.29B | 1.32B | 2.00B | 1.50B | 1.66B | 2.56B | 2.94B | 3.27B | 1.64B | - |
| Capital Expenditure | 266M | 204M | 255M | 245M | 294M | 370M | 322M | 322M | 283M | 217M | 119M |
| Free Cash Flow | 1.21B | 1.08B | 1.07B | 1.76B | 1.21B | 1.28B | 2.24B | 2.61B | 2.99B | 1.42B | -3.16B |
| Ratios | |||||||||||
| ROE | 14.0% | 11.3% | 10.4% | 9.9% | 10.1% | 9.0% | 9.2% | 9.2% | 3.6% | 5.9% | 6.4% |
| ROA | 5.6% | 4.7% | 4.2% | 3.8% | 3.5% | 3.1% | 3.5% | 3.4% | 1.4% | 2.3% | 2.5% |
| Net Profit Margin | 2.9% | 2.6% | 2.8% | 2.4% | 2.4% | 2.0% | 2.0% | 2.1% | 0.9% | 1.5% | 1.7% |
| Debt to Equity | 0.18x | 0.17x | 0.23x | 0.25x | 0.26x | 0.28x | 0.22x | 0.23x | 0.25x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China National Accord Medicines Corp Ltd dividends
- Dividend yield
- 5.73%
- Forward dividend
- 0.71 HKD
- Payout ratio
- 34.9%
- Ex-dividend date
- Jun 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 386M | 0.69 | 34.9% |
| 2024 | CNY 604M | 1.08 | 94.0% |
| 2023 | CNY 559M | 1.00 | 35.0% |
| 2022 | CNY 574M | 1.03 | 38.6% |
| 2021 | CNY 611M | 1.10 | 45.7% |
| 2020 | CNY 550M | 0.99 | 39.2% |
| 2019 | CNY 493M | 0.89 | 38.9% |
| 2018 | CNY 274M | 0.49 | 22.6% |
| 2017 | CNY 246M | 0.44 | 23.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on Jun 24, 2026.
Who owns China National Accord Medicines Corp Ltd
- Insiders 2.55%
- Institutions 3.58%
- Public & others 93.87%
- Shares outstanding 78.5M
- Free float 259M
China National Accord Medicines Corp Ltd company profile
- Company name
- China National Accord Medicines Corp Ltd
- Ticker
- 200028.SHE
- ISIN
- CNE0000009M8
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- Yizhi Pharmaceutical Building, Shenzhen, China, 518029
- Phone
- 86 755 2587 5140
- Website
- szaccord.com.cn
About China National Accord Medicines Corp Ltd
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. The company offers new and special drugs and medications for chronic diseases. It also provides traditional Chinese medicine, Western medicine, rehabilitation therapy, and various medical-related resources, as well as chemical drugs, OTC drugs, and health products. The company was formerly known as Shenzhen Health Mineral Water Corp., Ltd. China National Accord Medicines Corporation Ltd. was incorporated in 1993 and is headquartered in Shenzhen, China. China National Accord Medicines Corporation Ltd. operates as a subsidiary of Sinopharm Group Co., Ltd.
China National Accord Medicines Corp Ltd management
4- Mr. Guolin GuDeputy GM, CFO, General Counsel & Chief Compliance Officer · born 1976
- Mr. Chuan LiDeputy GM & Board Secretary · born 1977
- Mr. Jinxiong LiGM & Non-Independent Director · born 1979
- Xuefei WangAccounting Supervisor